Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Seeking Alpha / 2 minutes from now 1 Views
Comments